The Renin-angiotensin-aldosterone system (RAAS) plays a crucial role in the pathogenesis of hypertension, prompting the latest guidelines to recommend angiotensin II receptor blockers (ARBs) as first-line therapy (21, 22). This evidence concerns the gene REN and hypertensive disorder.